The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of gemcitabine versus gemcitabine and imatinib mesylate in patients with previously treated metastatic breast cancer.
Pashna Neville Munshi
No relevant relationships to disclose
Deborah Toppmeyer
No relevant relationships to disclose
Serena Tsan-Lai Wong
No relevant relationships to disclose
Shridar Ganesan
No relevant relationships to disclose
Katherine Hanna Tkaczuk
No relevant relationships to disclose
Mary E. Cianfrocca
No relevant relationships to disclose
Virginia G. Kaklamani
No relevant relationships to disclose
William John Gradishar
No relevant relationships to disclose
Robert A. Somer
No relevant relationships to disclose
Kanu Sharan
No relevant relationships to disclose
Generosa Grana
No relevant relationships to disclose
Pauline Marie O. Lerma
No relevant relationships to disclose
Lillian F. Pliner
No relevant relationships to disclose
Robert Wieder
No relevant relationships to disclose
Michael P. Kane
No relevant relationships to disclose
Sinae Kim
No relevant relationships to disclose
Antoinette R. Tan
No relevant relationships to disclose